Ohr Pharmaceutical Announces Positive Preclinical Safety Study Results for Squalamine Eye Drop for Wet-AMD
July 13, 2012
We’ve previously blogged about the Squalamine eye drops being developed by Ohr Pharmaceutical (OCTBB: OHRP) for treatment of wet AMD.
Earlier this week, OHRP announced positive results from a long term safety study of Squalamine eye drops, which indicated that the eye drop is safe when applied to the eye with no signs of ocular or systemic toxicity on long term administration.
Obviously, an eye drop for wet-AMD would be a “game changer” for patients currently requiring regular injections of Lucentis, Avastin or Eylea directly into the eye. So we’ll keep you posted on developments of this novel eye drop.
Click here to read the full press release.
You might also enjoy...
- Ohr Pharmaceutical Launches Clinical Trial to Evaluate Squalamine Eye Drops for Wet AMD
- Eye Drop to Treat Wet Macular Degeneration Granted Fast Track Designation by FDA
- DARPins Phase 2 Trial Results Fall Short
- OcuCure Therapeutics Eye Drop Shows Efficacy in Primates for AMD
- Lucentis Improves Vision in Retinal Vein Occlusions
Jump down to form below to submit your own comments